

CSD/BSE&NSE/CC/2024-25 May 21, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064 Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Notice regarding postponement of Schedule of Conference Call for Investors

Further to our letter dated May 20th, 2024, this is to inform you that the conference call for investors scheduled on Monday, May 27, 2024 at 07:00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, has been postponed and rescheduled on **Thursday, May 30, 2024 at 07:00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24**, to be declared on May 30, 2024. The revised invitation for conducting the conference call for investors is enclosed.

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

K Hanumantha Rao Company Secretary

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Suven Pharmaceuticals Ltd to host Q4 & FY24 Results Conference call on Thursday, May 30, 2024 @ 7.00 p.m

Suven Pharmaceuticals Ltd will conduct a conference call to discuss its Q4 & FY24 results performance. The management team will be represented by Mr. Annaswamy Vaidheesh (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer) & Mr. Himanshu Agarwal (Chief Financial Officer).

The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on May 30, 2024.

In order to pre-register: Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7303464&linkSecurityString=2d4f1c8848

Details of the conference call are as follows:

Timing	7.00 pm IST on Thursday, May 30, 2024	
Conference dial-in		
Primary number	+91 22 6280 1141/+91 22 7115 8042	
Singapore Toll Free Number	800 101 2045	
Hong Kong Toll Free Number	800 964 448	
USA Toll Free Number	1 866 746 2133	
UK Toll Free Number	0 808 101 1573	

- ENDS -

For further information please contact

Cyndrella Carvalho, (Head – Investor Relations)

Tel: +91 40 2354 9414

Suven Pharmaceuticals Limited

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649 / 77770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com